vs
Side-by-side financial comparison of Intellia Therapeutics, Inc. (NTLA) and Ponce Financial Group, Inc. (PDLB). Click either name above to swap in a different company.
Ponce Financial Group, Inc. is the larger business by last-quarter revenue ($31.4M vs $23.0M, roughly 1.4× Intellia Therapeutics, Inc.). Ponce Financial Group, Inc. runs the higher net margin — 36.3% vs -416.2%, a 452.4% gap on every dollar of revenue. On growth, Intellia Therapeutics, Inc. posted the faster year-over-year revenue change (78.8% vs 37.6%). Ponce Financial Group, Inc. produced more free cash flow last quarter ($54.6M vs $-69.4M). Over the past eight quarters, Ponce Financial Group, Inc.'s revenue compounded faster (23.7% CAGR vs -10.8%).
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
Ponce Financial Group, Inc. is a U.S.-based financial holding company operating Ponce Bank as its core subsidiary. It serves multicultural, immigrant and low-to-moderate income communities in the New York metro area, offering retail and commercial banking products including deposits, mortgages, small business financing and personal credit.
NTLA vs PDLB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $23.0M | $31.4M |
| Net Profit | $-95.8M | $10.1M |
| Gross Margin | — | — |
| Operating Margin | -428.9% | 43.6% |
| Net Margin | -416.2% | 36.3% |
| Revenue YoY | 78.8% | 37.6% |
| Net Profit YoY | 25.7% | 245.6% |
| EPS (diluted) | $-0.81 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $23.0M | $31.4M | ||
| Q3 25 | $13.8M | $26.7M | ||
| Q2 25 | $14.2M | $26.5M | ||
| Q1 25 | $16.6M | $24.6M | ||
| Q4 24 | $12.9M | $22.8M | ||
| Q3 24 | $9.1M | $20.2M | ||
| Q2 24 | $7.0M | $20.2M | ||
| Q1 24 | $28.9M | $20.5M |
| Q4 25 | $-95.8M | $10.1M | ||
| Q3 25 | $-101.3M | $6.5M | ||
| Q2 25 | $-101.3M | $6.1M | ||
| Q1 25 | $-114.3M | $6.0M | ||
| Q4 24 | $-128.9M | $2.9M | ||
| Q3 24 | $-135.7M | $2.4M | ||
| Q2 24 | $-147.0M | $3.2M | ||
| Q1 24 | $-107.4M | $2.4M |
| Q4 25 | -428.9% | 43.6% | ||
| Q3 25 | -808.9% | 32.8% | ||
| Q2 25 | -772.2% | 30.2% | ||
| Q1 25 | -726.6% | 32.5% | ||
| Q4 24 | -1059.9% | 19.6% | ||
| Q3 24 | -1589.0% | 15.2% | ||
| Q2 24 | -1998.6% | 21.8% | ||
| Q1 24 | -394.0% | 18.3% |
| Q4 25 | -416.2% | 36.3% | ||
| Q3 25 | -735.2% | 24.3% | ||
| Q2 25 | -710.8% | 23.0% | ||
| Q1 25 | -687.6% | 24.2% | ||
| Q4 24 | -1001.2% | 14.1% | ||
| Q3 24 | -1489.5% | 12.1% | ||
| Q2 24 | -2112.6% | 15.8% | ||
| Q1 24 | -371.3% | 11.8% |
| Q4 25 | $-0.81 | $0.43 | ||
| Q3 25 | $-0.92 | $0.27 | ||
| Q2 25 | $-0.98 | $0.25 | ||
| Q1 25 | $-1.10 | $0.25 | ||
| Q4 24 | $-1.27 | $0.11 | ||
| Q3 24 | $-1.34 | $0.10 | ||
| Q2 24 | $-1.52 | $0.14 | ||
| Q1 24 | $-1.12 | $0.11 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $449.9M | $126.2M |
| Total DebtLower is stronger | — | $596.1M |
| Stockholders' EquityBook value | $671.4M | $541.5M |
| Total Assets | $842.1M | $3.2B |
| Debt / EquityLower = less leverage | — | 1.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $449.9M | $126.2M | ||
| Q3 25 | $511.0M | $146.6M | ||
| Q2 25 | $459.7M | $126.6M | ||
| Q1 25 | $503.7M | $129.9M | ||
| Q4 24 | $601.5M | $139.8M | ||
| Q3 24 | $658.1M | $155.8M | ||
| Q2 24 | $691.1M | $103.2M | ||
| Q1 24 | $791.3M | $134.7M |
| Q4 25 | — | $596.1M | ||
| Q3 25 | — | $521.1M | ||
| Q2 25 | — | $536.1M | ||
| Q1 25 | — | $521.1M | ||
| Q4 24 | — | $596.1M | ||
| Q3 24 | — | $580.4M | ||
| Q2 24 | — | $680.4M | ||
| Q1 24 | — | $680.4M |
| Q4 25 | $671.4M | $541.5M | ||
| Q3 25 | $748.4M | $529.8M | ||
| Q2 25 | $715.3M | $521.1M | ||
| Q1 25 | $779.9M | $513.9M | ||
| Q4 24 | $872.0M | $505.5M | ||
| Q3 24 | $962.6M | $504.6M | ||
| Q2 24 | $971.1M | $497.7M | ||
| Q1 24 | $1.0B | $493.7M |
| Q4 25 | $842.1M | $3.2B | ||
| Q3 25 | $925.3M | $3.2B | ||
| Q2 25 | $898.9M | $3.2B | ||
| Q1 25 | $986.2M | $3.1B | ||
| Q4 24 | $1.2B | $3.0B | ||
| Q3 24 | $1.2B | $3.0B | ||
| Q2 24 | $1.2B | $2.8B | ||
| Q1 24 | $1.3B | $2.8B |
| Q4 25 | — | 1.10× | ||
| Q3 25 | — | 0.98× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 1.01× | ||
| Q4 24 | — | 1.18× | ||
| Q3 24 | — | 1.15× | ||
| Q2 24 | — | 1.37× | ||
| Q1 24 | — | 1.38× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-69.3M | $55.6M |
| Free Cash FlowOCF − Capex | $-69.4M | $54.6M |
| FCF MarginFCF / Revenue | -301.6% | 173.9% |
| Capex IntensityCapex / Revenue | 0.5% | 3.1% |
| Cash ConversionOCF / Net Profit | — | 5.48× |
| TTM Free Cash FlowTrailing 4 quarters | $-395.9M | $74.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-69.3M | $55.6M | ||
| Q3 25 | $-76.9M | $1.4M | ||
| Q2 25 | $-99.6M | $6.2M | ||
| Q1 25 | $-148.9M | $13.1M | ||
| Q4 24 | $-85.2M | $7.2M | ||
| Q3 24 | $-84.8M | $-14.6M | ||
| Q2 24 | $-58.2M | $-2.6M | ||
| Q1 24 | $-120.7M | $1.5M |
| Q4 25 | $-69.4M | $54.6M | ||
| Q3 25 | $-76.9M | $786.0K | ||
| Q2 25 | $-99.9M | $5.9M | ||
| Q1 25 | $-149.7M | $12.9M | ||
| Q4 24 | $-86.2M | $4.5M | ||
| Q3 24 | $-86.1M | $-15.0M | ||
| Q2 24 | $-59.2M | $-2.6M | ||
| Q1 24 | $-123.2M | $-315.0K |
| Q4 25 | -301.6% | 173.9% | ||
| Q3 25 | -558.2% | 2.9% | ||
| Q2 25 | -701.0% | 22.4% | ||
| Q1 25 | -900.1% | 52.6% | ||
| Q4 24 | -669.4% | 19.7% | ||
| Q3 24 | -945.2% | -74.1% | ||
| Q2 24 | -850.9% | -13.0% | ||
| Q1 24 | -425.7% | -1.5% |
| Q4 25 | 0.5% | 3.1% | ||
| Q3 25 | 0.2% | 2.3% | ||
| Q2 25 | 1.7% | 1.0% | ||
| Q1 25 | 4.4% | 0.6% | ||
| Q4 24 | 7.6% | 11.9% | ||
| Q3 24 | 14.0% | 2.0% | ||
| Q2 24 | 14.5% | 0.3% | ||
| Q1 24 | 8.7% | 8.7% |
| Q4 25 | — | 5.48× | ||
| Q3 25 | — | 0.21× | ||
| Q2 25 | — | 1.01× | ||
| Q1 25 | — | 2.20× | ||
| Q4 24 | — | 2.46× | ||
| Q3 24 | — | -5.99× | ||
| Q2 24 | — | -0.80× | ||
| Q1 24 | — | 0.61× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NTLA
| Avencell Therapeutics Inc | $21.0M | 91% |
| Other | $1.0M | 4% |
| Avencell | $1.0M | 4% |
PDLB
Segment breakdown not available.
